Cirrhotic liver lead to some changes in pathophysiology such as reduction in liver blood flow, decrease some metabolic and synthetic function of the liver. Also there is a change in endothelial lining from hepatic sinusoid. These changes result in some consequences that are increase in drugs sensitivity and adverse events due to pharmacokinetic and pharmacodynamic influences. Treatments for complications cirrhosis induce polypharmacy. Therefore, hepatic cirrhosis patient are at risk for serious drug interactions. The outcome can be harmful if the inteactions causes an increase in the toxicity of the drug. To study drug interaction events from drug therapy in hospitalized hepatic cirrhosis patient. Samples were collected using purposive sampling methods. Both drug therapy and disease progress were followed prospectively until patient discharged from the hospital. Drug interactions events were recorded and evaluated according to some literature. Patients involved in this study were 85. The total number of drug interactions occured in this study were 5 cases (5,88%). All events is potential drug interactions. Potential drug interaction involved spironolactone, furosemide, kalium supplement, aminophylline, ranitidine, and digoxin. This study demonstrates that potential drug interactions were common among hepatic cirrhosis patient, and pharmaceutical care capable in reducing drug interactions events
